NCT03328845 - Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

November 30, 2020

Study Completion Date

November 20, 2021

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Toujeo SoloStar

Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.

DRUG

Tresiba

Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.

DRUG

Humalog Kwikpen

Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl

DRUG

NovoRapid

Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl

DRUG

Apidra

Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl

Trial Locations (1)

Regional University Hospital of Málaga, Málaga

All Listed Sponsors

lead

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

OTHER